RIDHIMA SOFTA: Open Payments
NPI 1275062044 · BAKERSFIELD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,277 in 17 payments from 9 companies in 2025. Trend: 2023 $1,846 · 2024 $1,445 · 2025 $1,277
Food & beverage: $1,277
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $234 |
| Lilly USA, LLC | 6 | $220 |
| PFIZER INC. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 1 | $110 |
| GlaxoSmithKline, LLC. | 1 | $78 |
| Novo Nordisk Inc | 1 | $75 |
| Phathom Pharmaceuticals, Inc. | 1 | $72 |
| Smith+Nephew, Inc. | 1 | $62 |
Products named: AIRSUPRA, CAPLYTA, NURTEC ODT, REXULTI, ZEPBOUND, AREXVY, Ozempic, VOQUEZNA.
Industry payments across CA — which companies pay providers there.
